Compare Hormel Foods Corp (HRL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Neurocrine Biosciences Inc — how do they compare? Hormel Foods Corp trades at $19.26 (market cap $10.69B), while Neurocrine Biosciences Inc trades at $141.34 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Hormel Foods Corp pays a 6.02% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HRL | NBIX | |
|---|---|---|
Market Cap | $10.69B | $14.36B |
Volume | 10,041,387 | 1,237,180 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $185.50 |
52-Week Low | $19.42 | $123.10 |
Typical Hold Time | 99 Days | 23 Days |
Enterprise Value | $12.67B | $14.37B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.55, down 1.66% with bearish technical signals. The stock shows mixed fundamentals with a P/E of 31.32 and net margin of 2.82%, while recent quarterly earnings have consistently beaten expectations. The company's $1.06B Brakebush acquisition aims to expand foodservice presence, though cash flow trends show volatility with 2025 net cash flow negative $71M.
Outlook remains cautious with analyst consensus at Hold (57%) and $24.25 price target suggesting 24% upside. Key risks include declining profit margins, high payout ratios, and integration challenges from recent acquisition. The 60-year dividend streak provides stability but raises sustainability concerns amid shrinking raises.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
